Approximate simulation times. by James M. Osborne (163443)

Subjects:

Table of parameters used in the models across case studies. by James M. Osborne (163443)

Subjects:

Table of parameters specific to the differential adhesion simulations. by James M. Osborne (163443)

Subjects:

Index Models for Sparsely Sampled Functional Data by Peter Radchenko (765235)

Subjects:

PyRates benchmarks. by Richard Gast (8129451)

Subjects:

Schematic of software layers. by Richard Gast (8129451)

Subjects:

Jansen-Rit and Montbrió model validations. by Richard Gast (8129451)

Subjects:

PyRates—A Python framework for rate-based neural simulations by Richard Gast (8129451)

Subjects:

Model structure in PyRates. by Richard Gast (8129451)

Subjects:

A two state Markov model with state-dependent fates (Model M3) quantitatively explains the experimentally measured decay rate and correlations in lineage related HCT116 cells. by Anton Iyer (22278981)

Subjects:

A summary of the HCT116 dataset. by Anton Iyer (22278981)

Subjects:

An age-structured model accurately predicts population growth rates from single-cell IMT distributions. by Anton Iyer (22278981)

Subjects:

Pre-cisplatin heterogeneity in inter-mitotic times arises from a single population of cycling cells. by Anton Iyer (22278981)

Subjects:

An age structured model (Euler-Lotka equation) accurately predicts population growth rates of both HCT116 and U2OS cells before cisplatin treatment. by Anton Iyer (22278981)

Subjects:

Inferring the underlying post-drug IMT and AT distributions from the experimentally measured, biased distributions. by Anton Iyer (22278981)

Subjects:

Schematics of models M0 to M3, highlighting the differences in timing and mode of cell fate determination of each model. by Anton Iyer (22278981)

Subjects:

Maintenance of barcode diversity before and after drug cannot be interpreted as a signature of drug-induced cell fates. by Anton Iyer (22278981)

Subjects:

A summary of the U2OS dataset. by Anton Iyer (22278981)

Subjects:

Age structured models fail to predict population decay rates for cells treated with cisplatin. by Anton Iyer (22278981)

Subjects:

Torando diagram summarizing one-way sensitivity analyses of mean and cost of implementing the recommended activities of the ICDM model per PHR clinic. by Limakatso Lebina (554886)

Subjects: